Abstract
In this chapter six important questions that affect every Urologist in daily clinical routine are posed and answered based on a literature search including systematic reviews, meta-analyses, randomized trials and observational studies. As references those articles with the highest available degree of evidence were chosen. Issues are the use of an immediate chemoinstillation after TUR-BT, BCG as maintenance therapy, treatment options for BCG refractory non-muscle invasive disease, indications for a second TUR-BT, influence of fluorescence endoscopy on tumor recurrence and the use of urinary markers other than cytology. Recommendation for each issue is ranked using the GRADE system.
| Original language | English (US) |
|---|---|
| Title of host publication | Evidence-Based Urology |
| Publisher | Wiley Blackwell |
| Pages | 304-313 |
| Number of pages | 10 |
| ISBN (Print) | 9781405185943 |
| DOIs | |
| State | Published - Jul 9 2010 |
Keywords
- BCG treatment, maintenance therapy - standard of care and BCG maintenance therapy
- Concomitant carcinoma in situ (CIS)
- EAU guidelines, advocating immediate cystectomy upon BCG failure
- Fluorescence cystoscopy and residual tumor/recurrence rate
- Immediate postoperative intravesical instillation - of chemotherapeutic agent
- Possible risk of BCG treatment - balanced for every patient individually (Grade 2B)
- Superficial bladder cancer treatment
- Therapeutic options, from single transurethral resection of bladder tumor (TURBT) with early post transurethral resection (TUR) instillation therapy over TURBT
- Transitional cell carcinoma (TCC) of bladder - fourth most frequently diagnosed malignancy
- Treatment of BCG-refractory nonmuscle-invasive TCC
UN SDGs
This output contributes to the following Sustainable Development Goal(s)
